Bio-Techne Corp
62.02-1.92 (-3%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · TECH · USD
Key Stats
Market Cap
9.66BP/E (TTM)
134.83Basic EPS (TTM)
0.46Dividend Yield
0.01%Recent Filings
10-K
FY2025 results
Bio-Techne's FY2025 revenue climbed 5% to $1.2B, with organic growth matching that pace as Protein Sciences drove topline momentum through strong proteomic tools and cell therapy uptake, while Diagnostics and Spatial Biology added 6% via molecular diagnostics and Lunaphore integration. Q4 sharpened the trend, accelerating sequential quarterly gains in consumables amid margin compression from product mix and incentive resets, yet adjusted gross margins held at 70.4% annually. Adjusted net earnings rose 8% to $306M, or $1.92 diluted EPS, buoyed by volume leverage but tempered by $41.8M arbitration costs and $80.5M held-for-sale impairments; liquidity stayed robust with $162M cash and $654M revolver availability, funding $276M buybacks and $50M dividends. No formal FY2026 guidance emerged, but restructuring eyes margin recovery. Geopolitical tensions could snag quarterly supply chains.
8-K
Bio-Techne Q4 results and divestiture
Bio-Techne reported Q4 fiscal 2025 revenue of $317.0 million, up 4% reported but 3% organic, while full-year sales hit $1.2 billion with 5% organic growth. GAAP EPS plunged to ($0.11) from $0.25 due to an $83.1 million impairment on the Exosome Diagnostics business, now held for divestiture to sharpen focus on high-growth pillars like cell therapy and protein analysis; adjusted EPS rose to $0.53. The board declared a $0.08 quarterly dividend, payable August 29. Divestiture boosts profitability amid market uncertainty.
10-Q
Q3 FY2025 results
Bio-Techne's Q3 FY2025 net sales rose 4% y/y to $316.2M, with organic growth of 6% driven by pharma recovery in Protein Sciences, though foreign exchange and a held-for-sale business each trimmed 1%. Gross margin held steady at 67.9%, but operating income fell 42% y/y to $38.7M amid a $38.9M arbitration charge and elevated SG&A from restructuring and incentives, while diluted EPS dropped to $0.14 from $0.31. Cash from operations reached $189.4M YTD, funding $175.7M in share repurchases and leaving $140.7M in cash against $330M debt under a $1B facility maturing 2027. Restructuring costs hit $13.7M YTD for margin recovery. Tariffs and trade restrictions pose supply chain risks.
8-K
Q3 revenue up 6% organic
Bio-Techne reported third-quarter fiscal 2025 revenue of $316.2 million, up 4% reported and 6% organic, driven by 7% organic growth in Protein Sciences amid improving pharma conditions. Adjusted EPS rose to $0.56 from $0.48, with operating margin expanding to 34.9% via profitability drives, though GAAP EPS dipped to $0.14 due to a non-recurring arbitration award. The board declared a $0.08 quarterly dividend payable May 30 and launched a $500 million share repurchase program starting May 8. Strong execution persists.
8-K
Bio-Techne authorizes $500M buyback
Bio-Techne's board authorized a $500 million share repurchase program on April 30, 2025, replacing the prior 2022 authorization with no expiration date. The company can buy back shares via open market, private deals, or Rule 10b5-1 plans, guided by market conditions, stock price, capital needs, and performance to offset dilution from options. No obligation to repurchase exists. Repurchases will appear in future 10-K and 10-Q filings.
A
Agilent Technologies, Inc.
143.20-2.65
BIAF
bioAffinity Technologies, Inc.
2.48-0.01
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
BRKR
Bruker Corporation
37.74-0.98
DHR
Danaher Corporation
214.01-2.89
ILMN
Illumina, Inc.
95.03-2.77
LAB
Standard BioTools Inc.
1.19-0.08
SEER
Seer, Inc.
2.22-0.07
TMO
Thermo Fisher Scientific Inc
558.31+0.68
TWST
Twist Bioscience Corporation
32.21-1.36